{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"PIWORLD Investor Podcasts","title":"Poolbeg Pharma (POLB) Investor presentation - June 2024","html":"","width":"100%","height":180,"duration":2577,"description":"Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD and Chief Business Officer, David Allmond present an overview of their current programmes and opportunities, focussing on POLB 001, their oral delivery platforms, exclusive option agreement and their AI-powered research using human viral challenge data, followed by a Q&A session.\nJeremy Skillington PhD, Chief Executive Officer00:16 - Introduction03:06 - Programmes04:08 - 2024 highlights\nDavid Allmond, Chief Business Officer05:03 - POLB 001 & CRS08:01 - POLB 001's efficacy10:15 - POLB 001 Market Opportunity14:17 - POLB 001 support16:12 - Topical PTX & Behçet's Disease18:36 - Topical PTX 12 month option20:29 - Topical PTX Phase 2 trial\nJeremy Skillington PhD, Chief Executive Officer22:05 - Topical PTX outlook22:48 - Oral delivery platform25:02 - Artificial Intelligence programmes28:13 - Investment case\n29:30 - Q&A\nPoolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.\nPoolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.\nPoolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further...","thumbnail_url":"https://img.transistorcdn.com/oB5fNE4aIAia_YyTCKvE1PzrZQaD1Fjo_P7m7T9Aw_Y/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kOTJi/ODBiMzBmOGFhZWJi/MWEzYThkMzAyNmZm/MTdjZi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}